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ABSTRACT
RNA aptamers offer a potential therapeutic
approach to the competitive inhibition of DNA-
binding transcription factors. In previous reports
we described in vitro selection and characterization
of anti-NF-iB p50 and p65 RNA aptamers. We now
describe the further characterization of these
aptamers in vitro and in vivo. We show that sub-
saturating concentrations of certain anti-p50 RNA
aptamers promote complex formation with NF-iB
p50 tetramers, whereas anti-p65 R1 RNA aptamers
bind NF-iB dimers under all conditions tested.
Yeast three-hybrid RNA aptamer specificity studies
corroborate previous in vitro results, verifying that
anti-p50 and anti-p65 R1 RNA aptamers are highly
specific for NF-iB p502 and p652, respectively.
These studies introduce a novel T-cassette RNA
transcript that improves RNA display from a four-
way RNA junction. Mutagenesis of the anti-p65 R1
aptamer reveals tolerated substitutions, suggesting
a complex tertiary structure. We describe in vivo
selections from a yeast three-hybrid RNA library
containing sequences present early in the R1
SELEX process to identify novel anti-p65 RNA
aptamers, termed Y1 and Y3. These aptamers
appear to be compact bulged hairpins, reminiscent
of anti-p50. Y1 competitively inhibits the DNA-
binding domain of NF-iB p652 in vitro.
INTRODUCTION
The mammalian NF-kB–signaling cascade is activated in
response to inputs from many receptors (e.g. TNF, Toll,
cytokine, integrin and EGF), canonical and non-canonical
downstream–signaling molecules (e.g. IKKa/b/g, NIK),
and crosstalk from other pathways [e.g. PI3K, AKT,
CK2, etc. (1–3)]. These inputs convey information sensing
infection, adhesion and DNA damage. Depending on cell
type and both extra- and intracellular conditions, such
signals act in concert to activate NF-kB responses. NF-
kB transcription factors are key regulators of hundreds of
genes whose products induce speciﬁc immune responses,
proliferation, or promote cell survival by evasion of
apoptosis (4–6).
When proper NF-kB signaling is disrupted, NF-kB-
induced gene products (e.g. TNFa, cyclinD, IL-6, IL-8,
c-IAPs, Bcl family members, c-FLIP) contribute to
disease pathogenesis (7,8). There is strong experimental
support for the hypothesis that constitutive NF-kB acti-
vation in cancer directly contributes to drug resistance and
a malignant phenotype (9–17). Mechanisms of NF-kB
constitutive activation vary. Activation may result from
upstream receptor overexpression and/or aberrant kinase
signaling (18–23). Mutation of genes encoding NF-kB
transcription factors is unusual, making NF-kB transcrip-
tion factors attractive targets for therapeutic inhibition.
Previously, we used a SELEX approach to identify
anti-NF-kB p50 and p65 aptamers (Figure 1A) that bind
to the DNA-binding domain of NF-kB transcription
factors (24,25). These RNA aptamers were shown to act
as decoys that competitively inhibit DNA binding in vitro.
We exploited the yeast three-hybrid system (Y3H;
Figure 1B) to characterize and optimize anti-p50 RNA
aptamers (26,27). Others have also reported the utility
of the Y3H in mapping aptamer/protein-binding sites
(28,29).
Our long-term interests include understanding the basis
for, and speciﬁcity of, RNAs that bind to DNA-binding
proteins. Here we further characterize an anti-NF-kB p65
RNA aptamer termed R1 (25) and compare its speciﬁcity
to the anti-NF-kB p50 RNA aptamer that has previously
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predicted secondary structure of R1 (25). In previous bio-
chemical experiments (25), truncation analysis suggested
that 30-terminal sequences of R1 are important for high-
aﬃnity binding to homodimeric murine p65 (mp652).
When 25nt at the 30 terminus of R1 were replaced
by A25, aﬃnity for mp652 was reduced 100-fold. An
important feature within this 30 sequence is the G67–69 tri-
nucleotide (Figure 1A, underlined). Mutation of G67–69
to A67–69 resulted in a 20-fold reduction in aﬃnity for
mp652. These and other results of preliminary mutational
analysis suggested that, unlike the much more compact
31-nt anti-p50 RNA aptamer (24), both 50 and 30 R1
terminal sequences are necessary for high aﬃnity
binding to mp652 (25). One goal of the present work
was to identify anti-p65 RNA aptamers with simpler
structures that might facilitate in vivo applications.
We report experiments in vitro and in the Y3H to
characterize the interaction between anti-NF-kB RNA
aptamers and NF-kB proteins including (i) NF-kB
multimer preference (ii) NF-kB dimer speciﬁcity, (iii)
mutagenesis data and (iv) selection of new anti-p65
RNA aptamers.
MATERIALS AND METHODS
NF-iB protein expression and purification
The Rel homology region of human p652 was cloned into
a pET-15b derivative encoding a Tev protease cleavage
site and protein expressed in Escherichia coli strain
BL21(DE3). Cells were resuspended in 50mM sodium
phosphate buﬀer (pH 7.5) containing 300mM NaCl
(binding buﬀer), lysed with a high-pressure microﬂuidizer
Emulsiﬂex C-5 (Avestin), subjected to centrifugation at
20000 g for 30min, and the supernatant loaded onto a
nickel-NTA column (Qiagen), which was washed and
then eluted with aliquots of binding buﬀer containing
20mM and 500mM imidazole, respectively. The
hexahistidine tag was then cleaved with TEV protease
overnight at room temperature. The protein was puriﬁed
by Superdex 75 chromatography (Amersham Biosciences).
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Figure 1. (A) Predicted anti-NF-kB RNA aptamer secondary structures. Full-length R1, full-length anti-p50, and 31-nt version of anti-p50 (bracket)
are depicted with 50 terminal nt circled and nt of the non-randomized regions of R1 shaded. The trinucleotide G67–69 feature of R1 is underlined.
(B) Screening RNA libraries using the Y3H. Transcription of lacZ and HIS3 reporter genes (ﬁlled arrow at right) depends on a tri-molecular
interaction between integrated hybrid protein 1 (LexA/MS2 coat protein fusion, top), a hybrid protein 2 (GAL4AD/NF-kB family member, middle),
and a hybrid RNA composed of the MS2 recognition sequence and an early round or degenerate R1 library sequence cloned into the MS2 plasmid
by homologous recombination (bottom).
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proteins were expressed and puriﬁed as described (25).
Native electrophoretic RNA titration analysis of
aptamer/NF-iB complexes
Binding preferences for R1 RNA/p652 and full-length
or 31-nt anti-p50 RNA/p502 complexes were investigated
by incubating a constant concentration of p652 or p502
protein (100nM or 250nM) in 20ml-binding reactions
(20mM Tris–HCl, pH 8.0, 50mM NaCl, 1mM MgCl2)
with increasing concentrations of [
32P]-pCp-labeled
RNA. Reactions contained 0.25-, 0.5-, 1.0-, 1.5-, 2.0-,
3.0-, 4.0- or 5.0-fold molar excess RNA relative to
250nM protein, or 0.025-, 0.05-, 0.1-, 0.25-, 0.5-, 1.0 or
2.0-fold molar excess RNA relative to 100nM protein.
Components were incubated for 20min and electro-
phoresed through native polyacrylamide gels in 0.25 
TBE buﬀer. Complexes were detected and analyzed by
storage phosphor imaging.
Glutaraldehyde crosslinking analysis of aptamer/NF-iB
complexes
Binding reactions were performed as described for native
RNA titration analysis except in binding buﬀer lacking
BSA and salmon sperm DNA. Reactions were then
incubated in the presence of 0.02% glutaraldehyde for
30min at room temperature. Cross-linking reactions
were quenched with 0.25M glycine for 10min, heat
denatured in 2% SDS, and analyzed by electrophoresis
through 10% Bis–Tris NuPage polyacrylamide gels
(Invitrogen). Proteins were stained with Sypro Ruby
(Invitrogen) and imaged by UV transillumination.
Electrophoretic mobility shift assays and binding
affinity estimates
RNA molecules were 30 radiolabeled by ligation of [
32P]-
pCp using T4 RNA ligase. Aﬃnities for p652 protein were
determined by incubating 1nM radiolabeled RNA with
increasing concentrations of p652 in 20ml-binding
reactions containing 20mM Tris–HCl, pH 8.0, 50mM
NaCl, 1mM MgCl2,1 mg poly(dI dC), 0.5mg tRNA,
0.25mg/ml BSA, 5% (v/v) glycerol and 1mM DTT.
Binding reactions were incubated for 20min at room tem-
perature and electrophoresed through 29:1 acrylamide:
bisacrylamide native polyacrylamide gels in 0.25  TBE
buﬀer. Complexes were detected and analyzed by
storage phosphor imaging. Aﬃnity estimates were
obtained by ﬁtting the fractional saturation ( ) of the
radiolabeled nucleic acid target to the total protein
concentration (L):
  ¼
L
Kd þ L
1
where Kd is the equilibrium dissociation constant.
Hybrid protein constructs
Yeast GAL4 transcriptional activation domain fusions
with NF-kB proteins were generated by appending 40-bp
homology extensions to PCR products encoding the
appropriate NF-kB Rel homology regions and cloning
into expression vector pGAD424 (Clontech) via yeast
homologous recombination at the EcoRI site.
Yeast reporter gene assays
For quantitative lacZ reporter assays, yeast strains were
grown to mid-log phase, lysed by three liquid N2 freeze-
thaw cycles, and exposed to buﬀered CPRG or ONPG
substrate as described (27).
Cloning of anti-p65 RNAs present early in the R1
SELEX process
RNA sequences present at round 6 of the prior 12-round
in vitro selection that yielded the R1 aptamer (25) were
reverse-transcribed, PCR-ampliﬁed, and cloned into
pJ713, a version of pIIIA/MS2–2 (31), via yeast homolo-
gous recombination.
Synthesis of degenerate R1 RNA library
A degenerate R1 DNA oligonucleotide library was
synthesized by phosphoramidite methodology in the
Mayo Molecular Biology Core Facility. Phosphoramidite
mixtures were adjusted to yield  3% random mutagenesis
at each position.
T-cassette construction
A four-way RNA junction was designed to isolate the
secondary and tertiary structures of modular RNA
domains required for the Y3H. A pair of oligonucleotides
was extended into a duplex by overlap extension PCR.
This cassette was cloned into the pIIIA/MS2-2 RNA
expression plasmid (pJ207) using yeast homologous
recombination (32) to produce plasmid pJ1582. EcoRI
sites correspond to cloning sites in pIIIA/MS2-2, SphI,
SmaI and XhoI sites were introduced. In the present
experiments, MS-2 hairpin sequences where cloned at
the SmaI site and RNA aptamers at the SphI site. In
some cases random sequences were cloned at the XhoI
site. All cloning was performed by yeast homologous
recombination. The DNA sequence corresponding to the
T-cassette transcript (restriction sites in bold, aptamer
insertion sites in italics) is:
GA2CGA3CTCTG3AGCTGCGAT2G2CAGA2T2CCGT2
AGCA2G2C2GCAG2ACT2GCATGCT2ATC2TGCG2CG
CG3CGCGT3C3G3T2ACGCGC3GC2T2A2GTGT3CTCG
AGT2G2CACT2A2GCT2GCTA2CGGA2T2CC4ATATC2
A2CT2C2A2T3A2TCT3CT6A2T4CACT2AT3GCG
Y3H screening
The Y3H host strain L40–coat (31) was simultaneously
transformed with the GAL4AD/zebraﬁsh p652 (zp652)
expression plasmid (pJ1596), a linearized MS2 RNA
expression plasmid (pJ713), and the PCR-ampliﬁed candi-
date aptamer library ﬂanked with 40bp of homology to
the MS2 RNA expression plasmid. Alternatively, the
transformation contained a GAL4AD/murine p652
expression plasmid (pJ1448), the linearized T-cassette
RNA expression plasmid (pJ1582), and PCR-ampliﬁed
candidate aptamer library ﬂanked with 40bp of
6216 Nucleic Acids Research, 2009, Vol. 37,No. 18homology to the T-cassette RNA expression plasmid.
Transformation mixtures were plated on media selective
for the protein and RNA expression plasmids as well as
a selective level of 3-AT, and the plates were incubated
at 308C for 5–8 days. Large colonies were replica-plated
onto selective media and checked for lacZ reporter gene
activity by ﬁlter assay. RNA expression plasmids were
then isolated from lacZ positive transformants and
sequenced.
Northern blot analysis of RNA accumulation in yeast
Total RNA was extracted from Y3H strains as described
(33). Northern blot analysis was conducted as described
(26), simultaneously probing with radiolabeled oligo-
nucleotides complementary to the RNase P RPR1 leader
(50-AGCAC2ACAGCGTAC2ATGT) contained in both
the MS2 cassette and T-cassette, and to the U6 small
nuclear RNA (snRNA) (50-TC2T2ATGCAG4A2CTGC).
Signals were detected and analyzed by storage phosphor
technology.
RESULTS AND DISCUSSION
R1 and anti-p50 RNA aptamer binding to dimer and
tetramer forms of NF-iB
The availability of anti-NF-kB p50 and p65 RNA
aptamers allows for exploration of aptamer speciﬁcity
in vitro and in the cell nucleus. Because NF-kB proteins
participate in various homo-multimerization equilibria
(34) we began by studying the in vitro speciﬁcity of anti-
NF-kB RNA aptamers for NF-kB protein multimers.
Previously (25) we reported the titration of R1 RNA
over a range of concentrations relative to a constant con-
centration of p652. Analysis of the resulting complexes by
native gel electrophoresis showed that the anti-NF-kB p65
R1 RNA binds to p652 with a stoichiometry of one RNA
aptamer to one p65 dimer (p652), even at high RNA
excess. Likewise, a single anti-p50 RNA binds to p502
in solution (30), although the crystal complex studied by
X-ray diﬀraction shows two anti-p50 RNAs bound to the
p502 dimer (35). We analyzed R1 binding to p652 and anti-
p50 binding to p502 over a range of protein and RNA
concentrations where diﬀerent multimeric protein species
are possible. To clarify the NF-kB multimer state (e.g.
monomer, dimer, tetramer) in RNA complexes, we
compared electrophoretic gel mobility shift assays with
denaturing SDS polyacrylamide gel electrophoresis after
glutaraldehyde cross-linking.
Glutaraldehyde cross-linking was ﬁrst performed in
the absence of aptamers to determine the distribution
of NF-kB p50 and p65 monomers, homodimers and
homotetramers at nominal dimer concentrations of
100nM or 250nM (Figure 2A). The results show that
both recombinant p50 and p65 NF-kB proteins are
readily cross-linked as homodimers with no free
monomer detected. Some p50 homotetramer is evident
under these conditions (Figure 2A, lanes 6 and 8). We
then titrated radiolabeled R1 over a wide concentration
range relative to p652 (Figure 2B and C). Consistent with
previous results (25), only a single RNA:protein complex
was observed regardless of the p652 concentration or the
relative concentration of R1 (Figure 2B, lanes 12–18;
Figure 2C, lanes 30–36). The shifted species involves
only p652 as shown by glutaraldehyde cross-linking
(Figure 2B, lanes 3–9; Figure 2C, lanes 21–27). The
presence of a single complex independent of relative
concentrations of RNA and protein monomer conﬁrms
a 1:2 RNA:protein stoichiometry for R1:p65.
We repeated these experiments for complexes of anti-
p50 and NF-kB p502 protein, using either a 31-nt
truncated version of anti-p50 (Figure 2D and E) similar
to the RNA that had been studied by X-ray
crystallography (35), or the full-length (79nt) anti-p50
molecule identiﬁed from SELEX (Figure 2F and G)
(24). The 31-nt anti-p50 aptamer complex with p50
appears as a single species for all RNA:p50 ratios with
p502 at 250nM or 100nM (Figure 2D, lanes 12–18;
Figure 2E, lanes 30–36). Glutaraldehyde cross-linking
shows the p502 protein form to predominate (Figure 2D,
lanes 3–9; Figure 2E, lanes 21–27). These results are con-
sistent with our previous studies of the binding of the
31-nt anti-p50 RNA aptamer to p502 in solution (30).
Testing of the full-length anti-p50 RNA aptamer
with NF-kB p50 protein unexpectedly revealed two
RNA:protein complexes (Figure 2F and G). A slow-
migrating p50:anti-p50 complex was prevalent in the
presence of sub-stoichiometric RNA concentrations
relative to p502 (Figure 2F, lane 12, Figure 2G, lane 30).
Increasing RNA excess shifted the distribution to favor
a complex of higher mobility (Figure 2F, lanes 13–18,
Figure 2G, lanes 31–36). Glutaraldehyde cross-linking
studies revealed the basis for these two complexes
(Figure 2F, lanes 3–9, Figure 2G, lanes 21–27). As
previously shown in Figure 2A, 100nM or 250nM
dimer concentrations of recombinant p50 (but not p65)
protein include a signiﬁcant fraction of tetramer. The
full-length (79nt) anti-p50 RNA aptamer (but not the
31-nt truncated version) shows a strong binding prefer-
ence for p504, favoring this species even though p502
is the major protein form present (Figure 2F, compare
lanes 3 and 12; Figure 2G, compare lanes 21 and 30).
We hypothesize that the 79-nt anti-p50 RNA aptamer is
suﬃciently long that the RNA makes speciﬁc contacts
with one p50 subunit and simultaneous non-speciﬁc
contacts with an unoccupied monomer within the same
tetramer. This cooperative binding enhances the stability
of the complex. As the concentration of full-length anti-
p50 RNA is increased, p504 becomes saturated and excess
RNA aptamers bind to the p502 form of the protein
(Figure 2G, lanes 33–36).
To test that it is non-speciﬁc interactions that enhance
binding of full-length anti-p50 RNA aptamers to p504,w e
created binding reactions with a sub-saturating concentra-
tion of anti-p50, resulting in a predominant anti-p50:p504
complex (Figure 2H, lanes 2 and 11). We then added
increasing amounts of an unlabeled non-speciﬁc RNA
(in this case R1, which has low p50 aﬃnity) to determine
if the non-speciﬁc single-stranded RNA could compete the
labeled RNA aptamer into p502 complexes. The results
show that the non-speciﬁc RNA partially competes with
the speciﬁc full-length anti-p50/p504 complex (Figure 2H,
Nucleic Acids Research, 2009,Vol.37, No. 18 6217compare lanes 11 and 12). These results demonstrate
the existence of full-length anti-p50/p50 complexes with
stoichiometries of both 1:2 and 1:4. The latter are
stabilized by both speciﬁc and non-speciﬁc aptamer/
protein interactions.
RNA aptamer specificity for NF-iB proteins
Results of previous in vitro studies suggest that anti-p50
and anti-p65 R1 aptamers are highly speciﬁc for NF-kB
p502 and p652, respectively (25,35). To test anti-p65 R1
binding to p652 in vivo in the context of the yeast nucleus
we employed the Y3H [Figure 1B; (26,27,31,32)]. NF-kB
proteins were cloned and expressed as Gal4 activation
domain fusions in Y3H strains also expressing diﬀerent
tethered RNA aptamers in the context of the original
MS2 RNA expression plasmid. LacZ reporter gene acti-
vation was monitored by b-galactosidase assay, and scores
were normalized to those from the strain expressing
MS2-R1 and Gal4AD-murine p652 (Table 1). Anti-p50
recognized p502 but not p652 or Drosophila NF-kB
homologs tested in the Y3H. Similarly, low lacZ
reporter gene expression was detected for R1 with all
NF-kB family members except murine p652 (Table 1).
Glut.
250 nM p502
R1
[32P] - FLα α α α-p50
.25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x .25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x
.25x .25x .25x .25x .25x .25x .25x .25x .25x .25x .25x .25x .25x .25x .25x .25x
H
123456789 10 11 12 13 14 15 16
.25x .25x
17 18
F Glut.
250 nM p502
.25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x .25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x [32P] - FLα α α α-p50
150
75
37
1 23456789 1 0 1 1 1 2 1 3 1 4
.25x .25x .25x
15 16 17 18
Glut.
100 nM p502
[32P] - FLα α α α-p50
150
75
37
.025x .05x .1x .25x .5x 1.0x 2.0x .025x .05x .1x .25x .5x 1.0x 2.0x
19 20 21 22 23 24 25 26 27 28
G
29 30 31 32 33 34 35 36
.025x .025x .025x
Glut.
100 nM p502
[32P] -  31nt α α α α-p50 .025x .05x .1x .25x .5x 1.0x 2.0x .025x .05x .1x .25x .5x 1.0x 2.0x
150
75
37
150
75
37
E
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
.025x .025x .025x
Glut.
250 nM p502
[32P] - 31nt α α α α-p50 .25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x .25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x
150
75
37
D
1 2 3 4 5 6 7 8 9 1 01 11 21 3 1 41 5 1 61 71 8
.25x .25x .25x
C Glut.
100 nM p652
[32P] -  R1 .025x .05x .1x .25x .5x 1.0x 2.0x .025x .05x .1x .25x .5x 1.0x 2.0x
150
75
37
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
.025x .025x .025x
Glut.
250 nM p652
[32P] - R1 .25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x .25x .5x 1.0x 2.0x 3.0x 4.0x 5.0x
150
75
37
B
1 2 3 4 5 6 7 8 9 1 0 1 11 21 31 4 1 51 61 71 8
.25x .25x .25x
A Glut.
250 nM p652
100 nM p652
250 nM p502
100 nM p502
123 45 678
Figure 2. RNA aptamer speciﬁcities for diﬀerent NF-kB multimers. (A) Glutaraldehyde cross-linking of p50 and p65 proteins at 100nM and 250nM
nominal dimer concentrations. (B) and (C): R1 RNA titration of p652/R1 RNA complexes. Increasing concentrations of labeled R1 RNA (0.25-,
0.5-, 1-, 2-, 3-, 4-, 5-fold relative to 250nM p652) were incubated with p652 and electrophoresed on native gels (lanes 1–7) or cross-linked with
0.03% glutaraldehyde (Glut.) and electrophoresed on denaturing SDS gels (lanes 8–14). The analysis was repeated for 100nM p652.( D) and (E): 31-
nt anti-p50 RNA titration of p502/31-nt anti-p50 RNA complexes, performed as in (A). (F) and (G): Full-length anti-p50 RNA titration of p502/full-
length anti-p50 RNA complexes, performed as in (A). (H) Competition assay of full-length anti-p50/p504 complex. Labeled full-length anti-p50 RNA
was incubated at a concentration of 0.25-fold relative to 250nM p652, with or without 0.03% glutaraldehyde (lanes 1 and 9, respectively) or in the
presence of unlabeled R1 RNA competitor (non-speciﬁc for p50; 0.25-, 0.5-, 1-, 2-, 3-, 4-, 5-fold) relative to 250nM p652, and electrophoresed on a
native gel (lanes 2–8), or incubated with 0.03% glutaraldehyde and electrophoresed on a denaturing SDS gel. (lanes 10–16).
6218 Nucleic Acids Research, 2009, Vol. 37,No. 18These results corroborate in vitro analyses, conﬁrming that
the anti-p50 and R1 aptamers are highly selective for their
original SELEX NF-kB targets, over all other NF-kB
family members tested in the yeast assay.
An unexpected diﬀerence in Y3H signal between murine
and human p65 (Supplementary Table S1) prompted
further consideration. Miyakawa et al. (36) recently
reported that an anti-human IgG RNA aptamer was selec-
tive for IgG from human versus other vertebrates. Thus,
RNA aptamers have the potential for species selectivity.
Previous ﬁlter binding experiments with the anti-p50 RNA
aptamer suggested no obvious preference for murine p502
versus human p502 (24). The murine p652 ortholog was
used in the original SELEX experiment that identiﬁed R1
(25). The DNA recognition residues of p65 Loop L1 are
highly conserved among p65 orthologs, suggesting that
R1 should bind multiple forms of p652. We performed
electrophoretic gel mobility shift experiments comparing
puriﬁed human and murine p652 orthologs to estimate
equilibrium dissociation constants. Indeed, R1 displayed
similar aﬃnities for both murine p652 and human p652 in
these experiments (Supplementary Figure S1A). Y3H
experiments suggested R1 discrimination among murine,
human, and zebraﬁsh p652 orthologs, although all
produced lacZ reporter gene activities above background
(Supplementary Table S1). Western blotting showed that
similar levels of murine and human target proteins
accumulate in yeast (Supplementary Figure S1B).
Hybrid p652 proteins used to determine speciﬁcity in the
Y3H were also tested in the yeast one-hybrid system
(Y1H) with three copies of the NF-kB DNA consensus
sequence ([50-G4ACT3C2]) integrated upstream of lacZ
and HIS3 reporter genes. The results (Supplementary
Table S2) conﬁrm that cloned Gal4AD-p652 fusion
proteins are functional in yeast. The lack of correlation
between in vitro and in vivo R1 interaction with human
p652 is likely related to reduced human p65 protein
function detected in the Y1H. The  2-fold lower activity
of human p652 relative to murine p652 observed in the
Y1H is apparently ampliﬁed in the Y3H assay. We
conclude that anti-NF-kB RNA aptamers demonstrate
speciﬁcity for their targets in vivo.
Novel T-cassette improves Y3H RNA display and
facilitates R1 mutation screening
Protein:aptamer interactions in the Y3H system depend
on at least three factors: (i) intrinsic aﬃnity of the
isolated RNA insert for the target Gal4AD fusion
protein, (ii) retention of required RNA insert tertiary
structure when expressed within a larger transcript and
(iii) accessibility of the RNA insert to the target protein.
The combination of these three factors inﬂuences
aptamer/target protein interaction and reporter gene
readout. RNA ‘display’ describes the tertiary structure
and accessibility of an RNA aptamer in the Y3H.
Unlike the compact anti-p50 RNA hairpin, R1 contains
50 and 30 terminal sequences required for p652 recognition.
This may complicate preservation of R1 tertiary structure
in the context of Y3H RNA display transcripts.
To optimize R1 display in the conventional Y3H MS2
cassette we initially undertook systematic folding predic-
tions to identify ﬂanking sequences that maximize RNA
aptamer autonomy from the surrounding transcript
context. Computational approaches were used to predict
the folding autonomy of deﬁned or random RNA inserts
within the conventional Y3H display transcript for all
possible 6-bp (4096) or 10-bp (1048576) complementary
sequences that could form base-paired stems ﬂanking the
R1 aptamer. Optimal R1 stem sequences were then tested
in the Y3H in the presence of murine p652. In the case of
the optimized 6-bp stem, Y3H readout for the R1 aptamer
was marginally improved relative to a non-optimal stem,
but aptamer function remained sensitive to details of the
stem junction (data not shown). Several optimized 10-bp
stems were then included ﬂanking a 60-nt random
sequence library adjacent to a functional RNA aptamer.
When expressed with the target protein, aptamers with
random inserts ﬂanked by sequences for optimized stems
were twice as likely to produce detectable Y3H readouts.
However, even in this case Y3H readouts in the presence
of an adjacent 60-nt random sequence averaged only 3%
of readouts without the random sequence (data not
shown). Thus, optimally designed 6- or 10-bp GC-rich
Table 1. Binding activities of RNA aptamers in yeast and in vitro
Aptamer
a Protein
b b-Galactosidase
c
(MS2 cassette)
b-Galactosidase
c
(T-cassette)
Kd,nM
d
– AD 0.3 0.3 1.0 0.6 –
R1 AD 2.2 0.3 3.3 2.3 –
R1 AD-mp502 1.7 0.1 4.8 3.3 –
R1 AD-mp652 100 476 56 38 20
R1 AD-hp652 4.4 0.4 – –
R1 AD-zp652 4.5 0.3 – –
R1 AD-dorsal2 1.7 0.1 4.8 3.3 –
R1 AD-dif2 2.1 0.1 5.2 3.3 –
anti-p50 AD 1.9 0.1 8.5 0.5 –
anti-p50 AD-mp502 254 14 576 30 –
anti-p50 AD-mp652 2.5 0.6 7.1 1.0 –
anti-p50 AD-dorsal2 1.1 0.1 5.2 0.5 –
anti-p50 AD-dif2 0.9 0.1 2.4 0.5 –
Y1 AD 1.5 0.8 – –
Y1 AD-mp652 375 8 556 90 74 2
Y1 AD-hp652 38 9– –
Y1 AD-zp652 175 8– –
Y1-1 AD-mp65 113 16 552 90 86 10
Y1-1T AD-mp652 161 26 – 101 50
Y3 AD 1.1 0.7 – –
Y3 AD-mp652 73 10 456 142 94 31
Y3 AD-hp652 8.3 2.6 – –
Y3 AD-zp652 80 30 – –
Y3-1 AD-mp652 86 33 618 123 >2500
Y3-1T AD-mp652 90 25 – >2500
Dash indicates not tested.
aRNA aptamers cloned in MS2 cassette, T-cassette, or tested in isola-
tion in vitro. R1: 83nt; anti-p50: 31nt; Y1: 86nt; Y1-1: 40nt; Y1-1T:
39nt; Y3: 83nt; Y3-1: 32nt; Y3-1T: 33nt.
bAD: GAL4 activation domain.
cb-galactosidase activities normalized to positive control combination
MS2-R1-mp652 set at 100. Averages represent at least three indepen-
dent trials for each transformant.
dEquilibrium dissociation constant from electrophoretic gel mobility
shift data ﬁt to Equation (1) for target protein without activation
domain. Mean and standard deviation are shown based on at least
two repeats.
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tertiary structure.
We therefore created a ‘T-cassette’ RNA transcript to
stabilize modular RNA aptamer folding in the Y3H
system. The structure of the expressed RNA is designed
to isolate the aptamer domain from other RNA domains
emanating from a four-way helical junction. Figure 3A
compares the predicted secondary structures of the
original yeast RNAs (odd numbers) with the correspond-
ing T-cassette forms (even numbers). One arm of the
T-cassette transcript is occupied by a pair of MS2 RNA
hairpins, two arms are available for displaying experimen-
tal RNAs, and the fourth arm carries stabilizing yeast
RNAse P sequences derived from the original hybrid
RNA expression cassette (Figure 3A, Construct 2). To
test the T-cassette context for display of aptamers R1
and anti-p50, we measured b-galactosidase activities for
Y3H strains expressing either T-cassette RNAs or
MS2-RNAs in the presence of the appropriate NF-kB
family member (Table 1). Strains with T-cassette RNAs
showed consistently higher reporter gene activation. A
5-fold increase was observed for T-R1 versus MS2-R1,
and a  2-fold increase for T-anti-p50 versus MS2-anti-
p50 strain (Table 1). To conﬁrm equal accumulation of
T-cassette and MS2-RNAs in the Y3H strain, we har-
vested total RNA and performed northern blot analysis
(Figure 3B). MS2-RNAs (lanes 1, 3 and 5) are expressed at
levels comparable to T-cassette RNAs (lanes 2, 4 and 6).
Thus, the higher reporter gene activity induced by
T-cassette RNAs may result from improved aptamer
folding and accessibility. Importantly, the 5-fold increase
in b-galactosidase readout for the T-R1 strain versus the
MS2-R1 strain signiﬁcantly improves the dynamic range
available for mutation analysis.
R1 mutation analysis and secondary structure prediction
To improve our understanding of the R1 aptamer,
tolerated mutations were mapped in its primary
sequence. A random library of R1 mutants was created
in the context of the T-cassette and subjected to selection
for aptamer function in the Y3H with murine p652 as bait.
R1 variants were scored for in vivo function in the Y3H by
b-galactosidase assay. Twenty-four unique functional
variants were included in the analysis (Table 2). These
sequences carried an average of three mutations per R1
molecule. Measured b-galactosidase activities displayed an
11-fold range relative to the original R1 aptamer.
Interestingly, none of the 24 functional R1 mutants
contained mutations near the 30 terminus of the RNA.
These results suggest that 30 sequences are important for
R1 binding to p652 (25).
V1 nuclease susceptibility results for R1 (25) were used
to generate a revised R1 secondary structure prediction for
mapping tolerated mutations. The result is shown in
Figure 4. Panel A plots predicted R1 secondary structures
in terms of free energy change associated with folding and
concordance with V1 nuclease analysis (25). The arrow
indicates a favorable example. Panel B shows this fold
overlaid with V1 nuclease susceptibility. Panel C indicates
tolerated nucleotide substitutions, with changes that
strongly improve yeast three-hybrid function shown in
bold. Analysis of these mutagenesis data by three available
consensus structure prediction software programs was not
conclusive (Supplementary Figure S2).
Yeast selection of anti-p65 aptamers from early in the
SELEX process
While the R1 aptamer may be valuable in many settings,
we sought smaller anti-p65 RNA aptamers with compact
Table 2. Functional mutants of RNA aptamer R1 deﬁned in yeast
￿        ￿         ￿         ￿         ￿         ￿         ￿         ￿         ￿ β-galactosidasea
GAAGCTTACAAGAAGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 100±  7 
GAAGCTTACAAGAAGGACAGCACGAATACGACCTGCGTAAATCCCCCCCAATTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 165±24 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTACGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 156±22 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAAGCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 176±19 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA   98±23 
GAAGCTTACAAGAAGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGTTAGGGTAGTGGGTCGAATTCCGCTCA 186±38 
GAAGCTTACAAGAGGGCCACCACGAATAAGACCTGCGTAAATCCGCCCCATTTGTGTCAGGGTAGTGGGTCGAATTCCGCTCA 161±52 
GAAGCTTACAAGAGGGACAGCACGAATAAAGCCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA   75±14 
GAAGCTTACAAGAGGGACAGCACGAATGAAACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 122±18 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGCAAGGGTAGTGGGTCGAATTCCGCTCA   35±10 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTACGTAAATCCGCCCCATTTGTGTTAGGGTAGTGGGTCGAATTCCGCTCA 266±35 
GAAGCTTACAAGAGGGACAGCACGAATAAGACCTACGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 140±11 
GAAGCTTACAAGAAGGACAGCACGAATAAGACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 191±  4 
GAAGCTTACAAGAAGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCAGTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 118±31 
GAAGCTTACAAGAGGGACAGCACGAATAAGACCTGCGTAAATCCGCCCCATTTGTGCCAGGGTAGTGGGTCGAATTCCGCTCA 203±20 
GAAGCTTACAAGATGGACAGCACGAATGAAACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 129±14 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGTTAGGGTAGTGGGTCGAATTCCGCTCA 202±38 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAAGCCGCCCCATTTGTGTTAGGGTAGTGGGTCGAATTCCGCTCA 183±20 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAAGCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 224±11 
GATGCTTACAAGAGGGACATCACGAATAAAACCTGCGTAAAGCCGCCCCTTTTGTGTCAGGGTAGTGGGTCGAATTCCGCTCA 164±17 
GAAGCTTACAAGAGGGACAGCACGAATAAGACCTGCGTAAATCCGCCCCATTTGTGTTAGGGTAGTGGGTCGAATTCCGCTCA 227±28 
GAAGCTTACAAGAGGGACAGCACGAATAAGACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 158±  7 
GATGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA   92±13 
GAAGCTTACAAGAGGGACAGCACGAATAAAACCTGCGTAAATCCGCCCCATTTGTGTAAGGGTAGTGGGTCGAATTCCGCTCA 124±40 
GAAGCTTACAAGAAGGACAGCACGAATAAAACCTACGTAAAACCGCCCCATTTGTGTCAGGGTAGTGGGTCGAATTCCGCTCA 385±19 
aβ-galactosidase units normalized to positive control combinations set at 100. 
6220 Nucleic Acids Research, 2009, Vol. 37,No. 18structures to facilitate RNA display in in vivo experimental
settings. We used the Y3H to screen a library of RNA
sequences present at round 6 of the original murine p652
SELEX experiment that eventually gave rise to the R1
aptamer at round 12 (25) (Figure 5A). This approach
takes advantage of the RNA diversity present before con-
vergence of the SELEX process (27). The Round 6 RNA
library was cloned and expressed in the context of the
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GAL4AD-zebraﬁsh p652 (zp652), a related vertebrate
NF-kB target to select anti-p65 RNA aptamers with
broad speciﬁcity. Approximately 50000 RNA sequences
were screened for strong HIS3 activation (40mM 3-AT as
selective agent). Seven RNAs induced strong expression of
both HIS3 and lacZ (Figure 5B). Representative full
length (FL) aptamers Y1 and Y3 and derivatives
(Figure 5C) were inserted into MS2 RNA and/or
T-cassette contexts and tested in the Y3H. Table 1
summarizes aptamer interactions in yeast. Strikingly, the
Y1/mp652, Y1/hp652 and Y1/zp652 strains displayed 4-, 8-
and 39-fold higher lacZ reporter gene activation relative
to the corresponding yeast strains expressing R1. Our
previous studies demonstrated that R1 could not be
readily truncated (25). In contrast, Y1-1 and Y3-1
truncations proved to be functional in the Y3H, activating
lacZ by 33 and 120% of full-length Y1 and Y3 RNAs,
respectively (Table 1). Truncated variants of Y1 and Y3
containing tetraloop sequences were at least as eﬀective
(Table 1). The same constructs were also evaluated in
the improved T-cassette context (Table 1). The results
again indicate superior aptamer presentation in the
T-cassette with reporter gene activation often 5- to
7-fold higher than for aptamers presented from the
conventional MS2 cassette. Interestingly, Y1 and Y3
aptamers and derivatives were all comparable to R1 in
binding mp652 in the T-cassette context (Table 1).
We tested the anti-NF-kB p65 Y1, Y3 aptamers
and derivatives for binding to murine p652 in vitro.
Full-length Y1 and Y3 bound murine p652 in vitro with
aﬃnities 2- to 3-fold lower than for the R1 aptamer
(Figure 5D). Y1-1 and Y1-1T aptamers displayed
in vitro aﬃnities similar to full-length Y1. In contrast to
derivatives of Y-1, the Y3-1 and Y3-1T truncations that
functioned well in the Y3H did not bind mp652 in vitro
(Table 1). These results emphasize that aptamer function
in the context of a larger stabilizing RNA scaﬀold (Y3H)
may not reliably predict behavior of an isolated aptamer
in vitro. Because 2- to 3-fold lower aﬃnities were measured
for Y series aptamers versus R1 in vitro (Table 1), this
suggests that aptamer folding is particularly stabilized in
the T-cassette. We conclude that the Y1 anti-NF-kB p65
RNA aptamer shows particular promise because of its
compact folded structure and relaxed species speciﬁcity
relative to R1.
Y1 and Y1-1 aptamers as decoys for NF-iB
We have previously shown that anti-p65 R1 competes
with kB DNA for p652 protein binding in vitro (25). We
used competition gel mobility shift assays to test the
ability of the newly identiﬁed anti-p65 full length and
truncated Y1 RNA aptamers to compete with kB DNA
for binding to p652 (Figure 6). Radiolabeled kB DNA was
incubated in the absence of p652 (lane 1), in the presence
of p652 alone (lane 2) or together with various unlabeled
competitors: R1 (lanes 3–5), anti-p50 (lanes 6–8),
full-length Y1 (lanes 9–11), and truncated Y1 (lanes
12–14). Increasing unlabeled competitor nucleic acid
concentrations are indicated: 3-, 6-, or 12-fold molar
excess (lanes 3–5) or 25-, 50- or 75-fold molar excess
(lanes 6–14) relative to p652. Full length and truncated
Y1 RNAs compete with kB DNA for binding to the
DNA-binding domain of murine p652, suggesting that,
like R1, the binding site of these RNA aptamers
overlaps with the electrostatically favorable DNA-
binding domain of p65.
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There have been interesting recent eﬀorts to develop tran-
scription factor decoys based on DNA analogs [e.g. NF-
kB; (37)] or RNA molecules [e.g. heat shock factor; (38)
and b-catenin; (39)]. The work described here constitutes
additional progress toward the goal of developing a
‘toolbox’ of anti-NF-kB RNA aptamers for competitive
inhibition of p50 and p65 homo- and heterodimers. Native
gel electrophoresis and glutaraldehyde crosslinking studies
revealed a 1:2 stochiometry for both short anti-p50 and
anti-p65 aptamers interacting with NF-kB subunits. This
result conﬁrms the dimeric status of the transcription
factors under our chosen in vitro conditions, and
conﬁrms that a single aptamer binds each dimer under
both limiting and excess RNA concentrations. This
result conﬁrms and extends the previous stoichiometry
study of the anti-p50 aptamer (30), and indicates that
the 2:2 stoichiometry observed in the X-ray crystal struc-
ture is a special feature of that complex (35,40). Work
reported here also conﬁrms that the Y3H system
provides powerful veriﬁcation that the anti-NF-kB RNA
aptamers we have identiﬁed are speciﬁc for their intended
targets in an in vivo setting.
Future eﬀorts will be directed to achieve stable trans-
genic expression of RNA aptamers in model organisms
and cultured cells. The goal is to characterize the ability
of anti-NF-kB aptamers to artiﬁcially regulate gene
transcription by acting as molecular decoys for NF-kB
transcription factors.
The therapeutic potential of NF-kB RNA aptamers will
depend on development of delivery technologies allowing
RNA aptamers to reach high intra-nuclear concentrations
within speciﬁc organs and/or tissue types. Anti-NF-kB
RNA aptamer delivery via a viral vector strategy is an
option (41).
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